Interpreting Cancer Biomarker Testing - When Is Additional Testing Needed? (CNE)

Precision Medicine for Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Interpreting Cancer Biomarker Testing - When Is Additional Testing Needed?, participants will practice interpreting results from cancer biomarker tests, which test for dozens or hundreds of genomic variants and other biomarkers that may be driving cancer growth and may be targetable with treatment. Learn about when additional testing is indicated for further evaluation of genome-informed therapy, using the five parts of this module: an animated video providing overview information; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

To claim credit, follow the steps in the learning path.

CNE Information and Disclosures

Publication Date: January 11, 2024
Expiration Date: May 16, 2025

Target Audience
This activity is designed to meet the educational needs of practicing nurses and advanced practice nurses who provide oncology care.

Learning Outcome
Recognize the implication of results from biomarker tests in cancer patients. 

CNE Approval Statement
The Jackson Laboratory is co-providing this continuing nursing education activity with the American Medical Association and Scripps Health. This nursing continuing professional development activity was approved by the Northeast Multistate Division Education Unit, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 4 out of 5 questions correctly and 4) complete the evaluation.  

Contributors

• Emily Edelman, MS, CGC - The Jackson Laboratory
• Therese Ingram, MA - The Jackson Laboratory
• Lindsey Kelley, MPH, MS, CGC - The Jackson Laboratory
• Kalisi Logan, MS, CGC - The Jackson Laboratory
• Laura Nicholson, MD, PhD - Scripps Health
• Kate Reed, MPH, ScM, CGC - The Jackson Laboratory
• Jens Rueter, MD - The Jackson Laboratory
• Linda Steinmark, MS, CGC - The Jackson Laboratory
• Christine M. Walko, PharmD, BCOP, FCCP - Moffitt Cancer Center
• Laura West, PhD - The Jackson Laboratory
• Janet K. Williams, PhD, RN, FAAN - University of Iowa

Conflict of Interest Disclosure
This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest. Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course. All educational material has been peer-reviewed by external reviewers to assess for bias.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Kalisi Logan is an advisor for Igentify. Janet Williams is a stockholder in Pfizer. Ms. Logan's and Dr. Williams' contributions were peer reviewed by non-conflicted team members and modified as needed according to the results for the review to remove any identified commercial bias. 

References

Anderson, E., Hinton, A., Lary, C., et al. (2021). Community oncologists' perceptions and utilization of large-panel genomic tumor testing. BMC Cancer, 21(1):1273.

Aziza, S., Pezo, R., Jerzak, K., et al. (2021). Patients’ and Oncologists’ Knowledge and Expectations Regarding Tumor Multigene Next-Generation Sequencing: A Narrative Review. Oncologist, 26(8):e1359-e1371.

Buckenmaier, S., Mollica, M., Freedman, A., et al. (2021). Information Sources Used by Oncologists to Understand Multi-marker Tumor Panel Tests for Cancer Patients. J Cancer Educ, 36(5):1105-1114.

de Moor, J., Gray, S., Mitchell, S., et al. (2020). Oncologist Confidence in Genomic Testing and Implications for Using Multimarker Tumor Panel Tests in Practice. JCP Precis Oncol, 4(4):620-631.

Doig, K., Fellowes, A. & Fox, S. (2023). Homologous Recombination Repair Deficiency: An Overview for Pathologists. Mod Pathol, 36(3):100049.

Freedman, A., Klabunde, C., Wiant, K. et al. (2018). Use of Next-Generation Sequencing Tests to Guide Cancer Treatment: Results From a Nationally Representative Survey of Oncologists in the United States. JCP Precis Oncol, 2:PO.18.00169.

Fusco, M., Saeed-Vafa, D., Carballido, E., et al. (2021). Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precision Oncology, 5: 65-74.

Hall, M., D’Avanzo, P., Chertock, Y., et al. (2021). Oncologists' Perceptions of Tumor Genomic Profiling and the Communication of Test Results and Risks. Public Health Genomics, 24(5-6): 304-309.

Lazure, P., Parikh, A., Ready, N., et al. (2022). Challenges associated with the integration of immuno-oncology agents in clinical practice. BMC Med Educ, 22(1):781.

Luchini C., Paolino G., Mattiolo P., et al. (2020). KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J Exp Clin Cancer Res 39(1):227.

Mandelker, D., Donoghue, M., Talukdar, S., et al. (2019). Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol, 30(8), 1221-1231.

Manea, C., Badiu, D., Ploscaru, I., et al. (2022). A review of NTRK fusions in cancer. Ann Med Surg (Lond),  79: 103893. 

National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma, v2.2023. Retrieved 6/29/23.

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers, v2.2023. Retrieved 6/29/23.

Shah M., Hogstetter W., Kennedy E. et al. (2021). Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. JCO 39(28): 3182-3184.

Tomlins S., Hovelson D., Suga J. et al. (2021). Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. JCO Precis Oncol. 19(5):PO.20.00472. 

Hardware/Software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.

Disclaimer 
All information in Precision Medicine for Your Practice is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Precision Medicine for Your Practice. Reliance on any information in Precision Medicine for Your Practice is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Precision Medicine for Your Practice.